Le Lézard
Classified in: Health, Science and technology
Subject: Stock Sale/Buyback

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)


Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today reported that on February 14, 2022, the company granted non-statutory stock options to purchase an aggregate of 32,425 shares of the company's common stock to 17 newly hired employees, including seven newly hired employees based in India. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

The stock options have an exercise price of $26.99 per share, equal to the closing price of Schrödinger's common stock on February 14, 2022. Each stock option has a ten-year term and vests over four years, with 25 percent of the shares underlying the option vesting when the employee completes 12 months of continuous service measured from the employment start date and the balance of the shares vesting as follows: (i) for U.S.-based new hires, in a series of successive equal monthly installments of 1/48 of the original number of shares upon the employee's completion of each additional month of service over the 36 months following the first anniversary of the employment start date; and (ii) for India-based new hires, in a series of successive equal annual installments of 1/4 of the original number of shares upon the employee's completion of each additional year of service over the three-year period following the first anniversary of the employment start date. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the company's 2021 Inducement Equity Incentive Plan.

About Schrödinger

Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger's multidisciplinary drug discovery team also leverages the software platform to advance collaborative programs and its own pipeline of novel therapeutics to address unmet medical needs.

Founded in 1990, Schrödinger has over 500 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Twitter, or visit our blog, Extrapolations.com.


These press releases may also interest you

at 09:25
Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company, today released its 2021 Sustainability Report detailing its activities regarding its involvement in environmental, social and governance matters....

at 09:15
The 'Synthetic Biology Market - Global Outlook and Forecast 2022-2027' report has been added to ResearchAndMarkets.com's offering. The global synthetic biology market is expected to grow at a CAGR of 25% during 2022-2027.Synthetic biology is a new...

at 09:15
Illumina, Inc. , a global leader in DNA sequencing and array-based technologies, today announced that on September 30, its Illumina Genomics Forum (IGF) will feature Bill Gates, co-chair of the Bill & Melinda Gates Foundation, who will deliver a...

at 09:07
Beacon Biosignals, a startup that applies AI to EEG to unlock precision medicine for neurological and psychiatric disorders, presented research at the Alzheimer's Association International Conference, which took place July 31?Aug. 4, 2022, in San...

at 09:06
Caribbean healthcare workers can expect to continue to be recruited to live and work abroad over the next few years, suggests Joseph Boll, CEO of Caribbean Employment Services Inc. The market-leading online talent acquisition service headquartered in...

at 09:05
Pulmatrix, Inc. , a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSEtm technology, today announced second quarter financial results for 2022 and provided a...



News published on 17 february 2022 at 08:35 and distributed by: